Record Revenue Growth (Fiscal 2025)
Fiscal 2025 revenue $32.9M vs $27.3M prior year (+20% YoY). Q4 2025 was a record $11.0M (vs $10.5M, +5% YoY). Management attributes strong top-line momentum to multiple retail programs and product launches.
Very Strong Q1 2026 Guidance and Walmart Rollout
Q1 2026 revenue guidance of $25M–$27M driven by expansion into ~1,367 Walmart stores (additional ~1,000 stores), expanded scrubs styles and other major retailer launches. Scrubs program uses a 52-week replenishment model and represents ongoing, non-seasonal demand.
Brand Transition in Intimates with Margin Upside
Company did not renew Maidenform license and launched its own intimate apparel brand. This removes ~10% royalty/advertising contribution, management reports the new brand is selling better than the prior license and intimate apparel carries high gross margins (mid-40s to low-50s), supporting future blended margin recovery.
Tariff Clarification and Potential Refund
Prior IEEPA tariffs that materially pressured margins have been struck down and replaced by a more manageable 10% tariff. Company is lodging a refund claim of ~USD 600,000 (≈CAD 800,000) for improperly charged tariffs; management expects tariff clarity to enable better pricing and margin recovery.
Improved Cash Position and Inventory Build to Support Growth
Cash increased to $3.8M from $2.1M YoY. Inventories were intentionally increased to $21.0M (from $10.1M) to support the large Q1 cadence and retailer rollouts, demonstrating preparedness to service major retailer openings and larger orders.
Confirmed Clinical Data and Differentiated Product Value
Scrubs and technology backed by a peer‑reviewed clinical trial and supporting data; management emphasizes unique clinically proven positioning in retail (a clear differentiator) and is pursuing hospital, hospitality, travel and other vertical opportunities.
Operational Investment and Profitability Targets
One-time ERP and operating investments made to scale the business (ERP investment cited at ~CAD 0.5M total with majority in 2025). Management targets adjusted EBITDA margin of ~15% in 2026 and up to ~20% in 2027 as revenues scale and one-off costs recede.